Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TetraLogic Ends Birinapant MDS Trial After No Clinical Benefit Seen Over Placebo

This article was originally published in Scrip

Executive Summary

TetraLogic Pharmaceuticals Corp has ended a placebo controlled Phase II study of birinapant co-administered with azacitidine in first line patients suffering from the blood disorder myelodysplastic syndromes (MDS) after the SMAC-mimetic failed to show any clinical benefit over placebo.


Related Content

Medivir's Oncology Asset Purchase Seals TetraLogic's Death





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts